Long-term Continuous Intraperitoneal Insulin Infusion with an Implanted Remote-Controlled Insulin Infusion Device

Irsigler, K; Kritz, H; Hagmüller, G. W.; Franetzki, M; Prestele, K.; Thurow, Horst; Geisen, K.

doi:10.2337/diab.30.12.1072

Cited by 47 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the insulin pumps used in the test were the Siemens Promedos E 1 (external) [17] and Promedos 1 1 (implantable) [18,19], the Medtronic implantable drug administration device [18], the Pacesetter implantable medication system [18], and the Infusaid constant basal rate device [18,20]. In each case, the original catheter supplied by the pump manufacturer was used, since it must be considered an integral part of the system.…”

Section: Methodsmentioning

confidence: 99%

Chemical stability of insulin in a delivery system environment

Grau

1985

Diabetologia

View full text Add to dashboard Cite

Exposure of insulin solutions to elevated temperatures for prolonged periods of time will inevitably lead to chemical modifications of the hormone. Contact with different materials in dosing devices, other design-related factors and motion appear to be chemically more detrimental than storage in glass vials at the same temperature. An in vitro test, designed to mimic the in vivo situation, consisted of delivery of insulin at 37 degrees C while the device was constantly moved on a shaking apparatus. Insulin quality was assessed using high performance liquid chromatography. A polyethylenepolypropylene glycol-stabilized neutral human insulin solution (HOE 21 PH) was used. A single insulin derivative is the major modification product which, after passage of the complete infusion system, amounts to up to 10%. The biological potency of the derivative is indistinguishable from native insulin. Delivery of acidic insulin under implant conditions, leads to extensive and multiple insulin derivatization, even though the biological potency remains 95% after 4 weeks.

show abstract

Section: Methodsmentioning

confidence: 99%

Chemical stability of insulin in a delivery system environment

Grau

1985

Diabetologia

View full text Add to dashboard Cite

show abstract

“…infusion devices [59,60]. Implanted refillable pumps [61] have promised ultra-rapid pharmacokinetic dosing profiles of insulin with first-pass hepatic signalling in the portal circulation. These advantageous features have stimulated interest in novel i.p.-compatible insulin analogue formulations; desiderata include insulins with even more rapid onset of activity, shorter duration and greater formulation stability compared with the insulin therapeutics currently on the market.…”

Section: Mechanical Systemsmentioning

confidence: 99%

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

et al. 2021

View full text Add to dashboard Cite

Insulin replacement therapy for diabetes mellitus seeks to minimise excursions in blood glucose concentration above or below the therapeutic range (hyper-or hypoglycaemia). To mitigate acute and chronic risks of such excursions, glucose-responsive insulindelivery technologies have long been sought for clinical application in type 1 and long-standing type 2 diabetes mellitus. Such 'smart' systems or insulin analogues seek to provide hormonal activity proportional to blood glucose levels without external monitoring. This review highlights three broad strategies to co-optimise mean glycaemic control and time in range: (1) coupling of continuous glucose monitoring (CGM) to delivery devices (algorithm-based 'closed-loop' systems); (2) glucose-responsive polymer encapsulation of insulin; and (3) mechanism-based hormone modifications. Innovations span control algorithms for CGM-based insulin-delivery systems, glucose-responsive polymer matrices, bio-inspired design based on insulin's conformational switch mechanism upon insulin receptor engagement, and glucose-responsive modifications of new insulin analogues. In each case, innovations in insulin chemistry and formulation may enhance clinical outcomes. Prospects are discussed for intrinsic glucose-responsive insulin analogues containing a reversible switch (regulating bioavailability or conformation) that can be activated by glucose at high concentrations.

show abstract

“…Moreover, implantable pumps were developed that could deliver insulin through the intraperitoneal route [119,120]. This pump delivered a small insulin amount daily.…”

Section: Insulin Pumpmentioning

confidence: 99%

Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update

et al. 2021

View full text Add to dashboard Cite

The occurrence of diabetes mellitus (DM) is increasing rapidly at an accelerating rate worldwide. The status of diabetes has changed over the last three generations; whereas before it was deemed a minor disease of older people but currently it is now one of the leading causes of morbidity and mortality among middle-aged and young people. High blood glucose-mediated functional loss, insulin sensitivity, and insulin deficiency lead to chronic disorders such as Type 1 and Type 2 DM. Traditional treatments of DM, such as insulin sensitization and insulin secretion cause undesirable side effects, leading to patient incompliance and lack of treatment. Nanotechnology in diabetes studies has encouraged the development of new modalities for measuring glucose and supplying insulin that hold the potential to improve the quality of life of diabetics. Other therapies, such as β-cells regeneration and gene therapy, in addition to insulin and oral hypoglycemic drugs, are currently used to control diabetes. The present review highlights the nanocarrier-based drug delivery systems and emerging treatment strategies of DM.

show abstract

Long-term Continuous Intraperitoneal Insulin Infusion with an Implanted Remote-Controlled Insulin Infusion Device

Cited by 47 publications

References 1 publication

Chemical stability of insulin in a delivery system environment

Chemical stability of insulin in a delivery system environment

‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues

Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update

Contact Info

Product

Resources

About